SKYRIZI is indicated for the treatment of adult patients with moderately to severely active Crohnʼs disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.1
TRAINING PATIENTS TO MANAGE THEIR TREATMENT EXPERIENCE
At-Home Maintenance: Subcutaneous Every 8 Weeks1
DOSING CONSIDERATIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in use of the OBI. Provide proper training to patients and/or caregivers on the use of the OBI of SKYRIZI according to the Instructions for Use.1
Find patient support materials on dosing
Indication1
SKYRIZI is indicated for the treatment of adult patients with moderately to severely active Crohnʼs disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Important Safety Information1
Affiliate to insert local ISI.
Reference: 1. SKYRIZI [Summary of Product Characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co; January 2024.